Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Glugor, Penang, Malaysia.
School of Pharmaceutical Science, Universiti Sains Malaysia, Glugor, Penang, Malaysia.
Int J Biol Macromol. 2021 Aug 31;185:485-493. doi: 10.1016/j.ijbiomac.2021.06.146. Epub 2021 Jun 24.
Co-existence of Japanese Encephalitis virus (JEV) with highly homologous antigenic epitopes results in antibody-based serodiagnosis being inaccurate at detecting and distinguishing JEV from other flaviviruses. This often causes misdiagnosis and inefficient treatments of flavivirus infection. Generation of JEV NS1 protein remains a challenge as it is notably expressed in the form of inactive aggregates known as inclusion bodies using bacterial expression systems. This study evaluated two trxB and gor E. coli strains in producing soluble JEV NS1 via a cold-shock expression system. High yield of JEV NS1 inclusion bodies was produced using cold-shocked expression system. Subsequently, a simplified yet successful approach in generating soluble, active JEV NS1 protein through solubilization, purification and in vitro refolding of JEV NS1 protein from inclusion bodies was developed. A step-wise dialysis refolding approach was used to facilitate JEV NS1 refolding. The authenticity of the refolded JEV NS1 was confirmed by specific antibody binding on indirect ELISA commercial anti-NS1 antibodies which showed that the refolded JEV NS1 was highly immunoreactive. This presented approach is cost-effective, and negates the need for mammalian or insect cell expression systems in order to synthesize this JEV NS1 protein of important diagnostic and therapeutic relevance in Japanese Encephalitis disease.
日本脑炎病毒(JEV)与高度同源的抗原表位共存,导致基于抗体的血清学诊断在检测和区分 JEV 与其他黄病毒时不准确。这常常导致黄病毒感染的误诊和治疗效率低下。JEV NS1 蛋白的产生仍然是一个挑战,因为它在细菌表达系统中以称为包涵体的无活性聚集体的形式显著表达。本研究评估了两种 trxB 和 gor 大肠杆菌菌株通过冷休克表达系统生产可溶性 JEV NS1。使用冷休克表达系统产生了高产量的 JEV NS1 包涵体。随后,通过包涵体中 JEV NS1 蛋白的溶解、纯化和体外重折叠,开发了一种简单但成功的方法来产生可溶性、活性 JEV NS1 蛋白。逐步透析复性方法用于促进 JEV NS1 复性。通过间接 ELISA 商用抗 NS1 抗体特异性结合来验证复性 JEV NS1 的真实性,结果表明复性 JEV NS1 具有高度免疫反应性。该方法具有成本效益,不需要使用哺乳动物或昆虫细胞表达系统来合成这种在日本脑炎疾病中具有重要诊断和治疗相关性的 JEV NS1 蛋白。